Zweig-DiMenna Associates’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-128,592
| Closed | -$197K | – | 85 |
|
|
2024
Q4 | $197K | Hold |
128,592
| – | – | 0.01% | 88 |
|
|
2024
Q3 | $256K | Hold |
128,592
| – | – | 0.03% | 84 |
|
|
2024
Q2 | $450K | Sell |
128,592
-191,538
| -60% | -$670K | 0.05% | 71 |
|
|
2024
Q1 | $887K | Hold |
320,130
| – | – | 0.08% | 109 |
|
|
2023
Q4 | $544K | Hold |
320,130
| – | – | 0.06% | 99 |
|
|
2023
Q3 | $330K | Hold |
320,130
| – | – | 0.04% | 106 |
|
|
2023
Q2 | $371K | Buy |
320,130
+198,500
| +163% | +$230K | 0.05% | 108 |
|
|
2023
Q1 | $184K | Sell |
121,630
-19,220
| -14% | -$29K | 0.02% | 104 |
|
|
2022
Q4 | $352K | Hold |
140,850
| – | – | 0.05% | 102 |
|
|
2022
Q3 | $594K | Buy |
140,850
+89,350
| +173% | +$377K | 0.13% | 78 |
|
|
2022
Q2 | $144K | Hold |
51,500
| – | – | 0.03% | 84 |
|
|
2022
Q1 | $295K | Buy |
+51,500
| New | +$295K | 0.04% | 90 |
|